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Abstract: Stage classification is an important underpinning of man-
agement of patients with cancer, and rests on a combination of three 
components: T for tumor extent, N for nodal involvement, and M for 
more distant metastases. This article details an initiative to develop 
proposals for the first official stage classification system for thymic 
malignancies for the 8th edition of the stage classification manu-
als. Specifically, the results of analysis of a large database and the 
considerations leading to the proposed N and M components are 
described. Nodal involvement is divided into an anterior (N1) and 
a deep (N2) category. Metastases can involve pleural or pericardial 
nodules (M1a) or intraparenchymal pulmonary nodules or metasta-
ses to distant sites (M1b).
Key Words: Staging, Prognosis, Thymoma, Thymic carcinoma, 
Stage classification
(J Thorac Oncol. 2014;9: S81–S87)
Stage classification is fundamental to management of patients with cancer because it provides a common lan-
guage regarding anatomical extent of disease. Progress in 
thymic malignancy has been slowed by the lack of a univer-
sal, clearly defined system. Therefore, the Thymic Domain of 
the Staging and Prognostic Factors Committee (TD-SPFC) of 
the International Association for the Study of Lung Cancer 
(IASLC) and the International Thymic Malignancies Interest 
Group (ITMIG) sought to develop a TNM stage classification 
system that would be applicable to both thymoma and thy-
mic carcinoma (TC).1 This has advantages in being consis-
tent with the general format of the American Joint Committee 
on Cancer (AJCC) and the Union for International Cancer 
Control (UICC) stage classification system. Furthermore, a 
single system for thymoma and TC provides simplicity, which 
is important in a rare disease.
Five TNM stage classification systems for thymic malig-
nancies have been previously proposed, but there is no official, 
widely adopted system.2 These schemes divide the N compo-
nent into two to four categories and the M component into two 
to three categories. Although there are similarities among the 
N and M categories in some of these systems, there are also dif-
ferences. The TD-SPFC created specific N and M workgroups 
to consider what would best serve the needs of the global medi-
cal community to inform the 8th edition of the AJCC/UICC 
stage classification for thymic malignancy. This article reports 
on the deliberations and outcomes of this process.
METHODS
A general overview of the database used for this analysis 
and the principles guiding the development of a stage classifica-
tion system have been described elsewhere.1,3,4 In summary, a 
large international retrospective database including more than 
10,000 patients overall was developed by the ITMIG and several 
other organizations (European Society of Thoracic Surgeons, 
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Japanese Association for Research in the Thymus [JART], 
Chinese Alliance for Research in Thymoma). The IASLC pro-
vided infrastructure and funding to allow an extensive analysis, 
which was performed by the Cancer Research And Biostatistics 
group to develop TNM-based, data-driven stage classification 
proposals to inform the 8th edition of the AJCC/UICC stage 
classification system. Papers describing details of the T compo-
nent and the stage grouping are provided elsewhere.3,4
Despite the large size of the database, details regarding 
the N or M status were available in only a subset of the patients. 
This reflects the fact that advanced thymic tumors are less com-
mon, the fact that data on resected patients was more readily 
available for inclusion in the database, and that retrospective 
data was most often collected according to traditional staging 
systems which often did not discriminate among details of N 
and M involvement. The vast majority of data with sufficient 
detail comes from JART. This organization and the country 
of Japan have had a long-standing commitment to gathering 
detailed data regarding extent of disease of thymic and other 
cancers. This was invaluable to the IASLC/ITMIG stage classi-
fication project (Fig. 1). Input was specifically sought out from 
the TNM committee of the Japan Lung Cancer Society (Jun 
Nakjima, Masaki Hara, Kazuya Kondo, Meinoshin Okumura, 
Yoshihiro Matsuno, Motoki Yano), because of the work that 
this group and others in Japan have done to investigate the 
impact of nodal involvement in thymic malignancies.
The limited amount of detailed data precluded being able 
to assess whether there were statistically significant differences 
in the outcomes of various cohorts. The analysis was based pri-
marily on a visual assessment that suggested a difference, simi-
larities of the N classification to a consensus-based ITMIG/
IASLC mediastinal thymic node map,5 similarities of the M 
classification to the Masaoka and Masaoka-Koga stage classifi-
cation systems (representing the two systems in most common 
use), practical considerations relative to the conduct of surgery 
for thymic malignancies and a consensus opinion about what 
was worthwhile to distinguish. Details of the statistical meth-
ods that were used where possible are described elsewhere.3
A collaborative process was conducted by ITMIG in 
conjunction with the TD-SPFC to develop a node map for 
thymic malignancies.5 This workgroup considered anatomical 
factors, surgical aspects, and existing node mapping systems 
(i.e., for lung, head, and neck cancers and previously proposed 
systems for thymic malignancy) to develop a proposed map. 
The product of this effort was remarkably similar to what the 
TD-SPFC group developed through analysis of the available 
data. The ITMIG node map workgroup and the TD-SPFC dis-
cussed and coordinated their efforts to produce a final node 
map and an N classification system that were congruent.
PROPOSED N COMPONENT CLASSIFICATION
The proposed N classification is shown in Table 1. The 
TD-SPFC proposes dividing nodal involvement into an ante-
rior (perithymic, N1) and a deep (N2) category, consistent 
with the definitions of these regions in the ITMIG/IASLC 
node map (Fig. 2).5 The anterior region extends from the hyoid 
bone to the diaphragm, bounded anteriorly by the sternum, 
posteriorly by the trachea (neck) and pericardium (chest), and 
laterally by the medial border of the carotid sheaths (neck) 
and the mediastinal pleura (chest). The distal boundaries of 
the deep region are defined by the medial edge of the trape-
zius muscle (neck) and the pulmonary hila (chest) laterally 
and the esophagus and vertebral column posteriorly. The deep 
region includes paratracheal, subcarinal, aortopulmonary 
window, hilar, jugular, and supraclavicular nodes. Involved 
nodes outside these regions (e.g., axillary, subdiaphragmatic) 
are outside the N category and considered a distant metastasis. 
Further details are provided elsewhere.5
The JART has conducted by far the best analysis of the 
incidence and location of node metastases from thymic malig-
nancies.6 Lymph node metastases were seen in 2% of 1064 
thymomas, 27% of 183 TCs, and 28% of 40 thymic neuroen-
docrine tumors (NETT). These node metastases were seen most 
often in what corresponds to the region defined here as N1: of 
node-positive patients 89% with thymoma, 69% with TC, and 
91% with NETT had involvement of N1 nodes, and 26% of thy-
moma, 30% of TC, and 45% of NETT had involvement of N2 
nodes (most with N2 involvement also had N1 involvement).6
In the ITMIG/IASLC database, a limited number of 
patients had sufficient detail reported to allow evaluation of 
outcomes for the proposed anterior and deep nodal regions. 
FIGURE 1.  Evaluable patients for the N and M component 
analysis. Diagram of evaluable patients available for analysis, 
by N and M characteristic, with the proportion contributed by 
the Japanese Association for Research in the Thymus (JART).
TABLE 1.  N, M Descriptors
Category Definition (Involvement of)a
N0 No nodal involvement
N1 Anterior (perithymic) nodes
N2 Deep intrathoracic or cervical nodes
M0 No metastatic pleural, pericardial, or distant sites
M1
  a Separate pleural or pericardial nodule(s)
  b Pulmonary intraparenchymal nodule or distant organ metastasis
aInvolvement must be pathologically proven in pathologic staging.
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Such detailed data were almost exclusively available from the 
patients contributed by JART. Nodes listed as N1 in JART 
correspond well with anterior intrathoracic (N1) nodes in 
the ITMIG/IASLC scheme; JART N2 nodes correspond to 
deep intrathoracic nodes in the ITMIG/IASLC scheme. These 
approximations were used to assess the outcomes of node 
involvement in the TD-SPFC classification proposal. There 
were few patients (n = 17) with involvement of neck nodes 
(JART N3) in the ITMIG/IASLC database. Following discus-
sion with the curators of the JART database, these were felt 
in general to correspond to deep cervical nodes (N2 in the 
ITMIG/IASLC map). Their outcome did track with that of 
intrathoracic N2 nodes (5-year OS, R any was 44% for JART 
N2 and 40% for JART N3). Hence the JART N3 nodes were 
included in the Cancer Research And Biostatistics analyses 
together with other ITMIG/IASLC N2 nodes. A priori it was 
thought that data on all patients regardless of R status (i.e., 
R any) would be most relevant, since an R0 cohort would be 
more selected and less applicable to clinical staging.
Examination of the available data shows that OS among 
patients with any R status is better for the N1 versus the N2 
category (5-year survival 69% versus 47%). This is more dif-
ficult to assess in R0 resected patients, because there are few 
in the N2 R0 groups; OS appears to be worse for N2 versus N1 
but the rate of recurrence is similar (Fig. 3). However, none of 
the differences reached statistical significance (including OS 
in the R any cohort). The overall rates of death (Table 2) also 
demonstrate that N2 is worse than N1 among R any patients. 
Overall rates of recurrence are difficult to assess because 
there are few R0 patients in the N2 category, and even fewer 
in which recurrence information was available.
The TD-SPFC proposes to distinguish N1 from N2 
nodes as outlined for several reasons. The speculation that 
involvement of nodes close to the thymus (N1) signifies less 
advanced or aggressive disease than involvement of deep 
(N2) nodes seems plausible. This is borne out at least quali-
tatively by the data in the ITMIG/IASLC database and by 
prior JART analyses,6,7 although the power to detect statistical 
significance for the difference is limited by the amount of data 
available. From a practical, clinical standpoint, the separation 
of anterior and deep regions is appealing because the anterior 
region nodes would be included in an extended thymectomy, 
whereas access to the deep region nodes would require extra 
effort. Furthermore, the separation is similar to what has been 
used by the JART in previous analyses and corresponds to the 
ITMIG/IASLC consensus-based node map developed by a 
parallel process.5–7 Finally, in the absence of data demonstrat-
ing that further subdivision (i.e., N3) distinguishes patients 
with a different prognosis, it seems that keeping it simpler is 
better.
Microscopic demonstration of involvement is needed to 
classify a node as involved by pathologic stage classification. 
Invasion by direct extension is counted as nodal involvement. 
There is no data to assess the impact of direct invasion ver-
sus a nodal deposit that is separate from the primary tumor. 
However, the TD-SPFC decided on this definition to be consis-
tent with the IASLC/AJCC/UICC definition for lung cancer.
To stage nodes accurately, ITMIG has proposed that 
anterior mediastinal nodes be routinely removed along with 
the thymus and encouraged a systematic sampling of deep 
nodes when resecting thymomas with invasion of mediasti-
nal structures (pericardium, lung, etc.).8 For TC, a systematic 
removal of both N1 and N2 nodes is recommended during 
curative-intent resection.8 A study specifically addressing the 
role of node dissection in TC (37 patients) also suggested that 
anterior and paratracheal nodes should be routinely dissected, 
especially when adjacent organs were invaded.9 A minimum 
number of 10 dissected nodes were suggested in that study, as 
this appeared to correlate with better survival.9
PROPOSED M COMPONENT CLASSIFICATION
The M component is divided into three categories: M0 if 
there are no metastatic sites, M1a if there are pleural or pericar-
dial nodules separate from the primary tumor mass, and M1b 
if there are distant (extrathoracic) metastases or pulmonary 
FIGURE 2.  ITMIG /IASLC Lymph Node Map. 
Anterior and deep node regions as depicted on axial 
images. Anterior region (blue); deep region (purple). 
For further detail see Bhora et al.5 (A) Thoracic inlet; 
(B) paraaortic level; (C) AP window level; (D) carina 
level. AA, ascending aorta; Az, azygos vein; CCA, 
common carotid artery; BR, bronchus; Clav, clavicle; 
DA, descending aorta; E, esophagus, IJV, internal 
jugular vein; LB, left main bronchus; LPA, left pul-
monary artery; LSPV, left superior pulmonary vein; 
PT, pulmonary trunk; RB, right main bronchus; RPA, 
right pulmonary artery; SVC, superior vena cava; Tr, 
trachea.
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intraparenchymal nodules (Table 1). One reason for this three-
way separation is that there may be a different mechanism of 
spread (i.e., local dissemination through the pleural or pericar-
dial space versus hematogenous spread, although this is based 
on rationale and speculation). It also appears that the extent 
of dissemination is different, and the implications for treat-
ment are generally viewed as different. Finally, the decision 
was also based on a visual impression that the outcome curves 
are different for M1a and M1b (Fig. 3).
The OS among N0 any R patients is better for the M1a 
versus the M1b category (5-year survival 71% versus 56%, 
Figure 3), although the differences are not statistically signifi-
cant. Overall rates of death among R any patients are worse for 
N0,1 M1b versus N0 M1a cohorts (45% versus 31%, Table 2). 
The limited data available make outcomes among R0 resected 
patients difficult to interpret.
The ability to evaluate outcomes for statistical signifi-
cance was limited given the size of the patient cohorts and 
by the nature of the database. The database primarily involves 
surgically resected patients; however, it is likely that the 
majority of patients diagnosed with M1a and especially M1b 
involvement from a thymic malignancy are managed nonsur-
gically. Thus, the resected M1b patients in the ITMIG/IASLC 
database represent a very selected subset of all M1b patients. 
Because of these considerations, the TD-SPFC weighed the 
rationale about the mechanism of spread and potential treat-
ment implications heavily and downplayed the observed out-
comes in M1b patients. A stage classification system that is 
applicable to all patients must take into account patients who 
are not resectable—at least conceptually and speculatively if 
data is not available for analysis.
The TD-SPFC evaluated whether there was a difference 
in outcomes of pleural nodules, pericardial nodules, or intra-
parenchymal pulmonary nodules. No difference was appar-
ent, although the number of patients with this level of detail 
was limited. The TD-SPFC also discussed whether pulmonary 
parenchymal nodules should be classified together with pleu-
ral and pericardial nodules. The decision was made to clas-
sify pulmonary parenchymal nodules as M1b. This was based 
primarily on the speculation of the mechanism of spread, and 
the consistency this afforded with the interpretation of the 
Masaoka and Masaoka-Koga stage classification systems.10 
The historical classification of pleural nodules together with 
pericardial nodules was retained (both are considered M1a). 
There were too few patients to analyze and no clear difference 
among these groups, although there was a slight suggestion 
of worse OS for pericardial versus pleural nodules in R any 
patients).
Examination of the nature of patients included in the 
M1b cohort reveals that the vast majority of these had pulmo-
nary parenchymal nodules. Those that had other distant sites 
FIGURE 3.  Outcomes of all patients by proposed N and M categories. Outcomes of all patients with a thymic malignancy of 
any type. A, Cumulative incidence of recurrence, R0 resected patients; (B) overall survival, R0 resected patients; (C) overall sur-
vival, all patients (any R status); point estimates at 5 and 10 years are provided in the tables. There are no statistically significant 
differences between the curves. CI, 95% confidence interval; Cum. Inc. of Recurrence, cumulative incidence of recurrence; N, 
total number of evaluable patients; OS, overall survival; R0, complete resection; Yr, year.
TABLE 2.  Total Proportion of Recurrences or Deaths
Recurrence, R0 Deaths, R0 Deaths, any R
% Events/n % Events/n % Events/n
Stage IVa 59 119/201 30 75/251 32 209/654
  N1 M0 54 21/39 28 11/40 33 18/54
  N0 M1a 61 94/154 30 61/203 31 179/579
  N1 M1a 50 4/8 38 3/8 57 12/21
Stage IVb 49 17/35 33 14/43 43 43/99
  N2 M0,1a 35 6/17 35 6/17 48 20/42
  N0,1 M1b 55 6/11 25 3/12 45 14/31
  N2 M1b/X
 + NX M1b
71 5/7 36 5/14 35 9/26
The total number of recurrences or deaths observed at any time out of the total 
number of evaluable patients in each category.
R, resection status; R0, complete resection.
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of disease but were included in the database are likely a very 
selected subgroup. It is also likely that many of the patients 
with pulmonary nodules may have been discovered inciden-
tally at the time of resection; caution is advised in extrapolat-
ing these outcomes to patients with preoperatively identified 
intraparenchymal pulmonary nodules.
The recurrence and survival outcomes of patients with 
N1 involvement are similar to those of patients with M1a 
involvement. In addition, the outcomes of patients with N2 and 
M1b involvement (or both) are similar (Fig. 3, Table 2). The N1 
and M1a cohorts were grouped into the stage group IVa and 
the N2 and M1b cohorts into stage group IVb, as is described 
elsewhere.3 However, these similar observed outcomes do not 
necessarily mean that the biological behavior is the same; fac-
tors influencing a propensity for nodal involvement and pleural 
involvement may be different. The outcomes for thymoma and 
TC followed similar trends to what was observed for all patients 
(N1 better than N2, M1a better than M1b, Supplemental Figure 
1, Supplemental Digital Content 1, http://links.lww.com/JTO/
A656). Therefore, although the number of patients is limited 
the proposed classification appears applicable to both thy-
moma and TC. NETT of the thymus were not included in either 
of these subsets and were too few to be analyzed separately.
DISCUSSION
Development of a uniform stage classification system is 
a major prerequisite for progress in treatment, particularly in 
an uncommon malignancy. The lack of an official stage clas-
sification has been an impediment which the IASLC/ITMIG 
initiative set out to address. The proposals defined in this arti-
cle and the companion papers pave the way for a worldwide 
uniform system starting with the 8th edition of the stage clas-
sification system.3,4
A comparison to the five previously proposed TNM 
classification systems reveals similarities and differences 
among the N classifications. The Yamakawa–Masaoka and 
Tsuchiya systems11,12 defined anterior mediastinal lymph 
nodes around the thymus as N1, intrathoracic lymph nodes 
other than anterior mediastinal lymph nodes as N2, and 
extrathoracic lymph nodes as N3. The WHO and Bedini 
systems13,14 defined N3 more specifically as scalene and/or 
supraclavicular lymph nodes. The Weissferdt–Moran system 
(for TC)15 considers only intrathoracic nodes in the N clas-
sification. The system proposed by the TD-SPFC is similar 
(but more detailed and specific) in defining intrathoracic N1 
and N2 nodes, but differs in classifying low cervical nodes 
adjacent to the upper poles of the thymus or slightly further 
removed (e.g., jugular or supraclavicular nodes) also as N1 
and N2, respectively.
The Yamakawa–Masaoka, Tsuchiya, Weissferdt–Moran, 
and WHO schemes define M1 as hematogenous or distant 
metastases.11,12,14,15 In these schemes, pleural or pericardial 
nodules are classified as T4. The Bedini scheme13 classifies 
distant metastasis as M1b. Pleural nodules are designated as 
M1a if they are posterior to the phrenic nerve and as T4 if 
they are anterior to the phrenic nerve. The TD-SPFC proposal 
is to classify separate pleural or pericardial nodules as M1a. 
This fits with what appears to be a difference in outcomes, a 
difference in treatment approaches, and in the mechanism of 
spread. Furthermore, this is consistent with the classification 
system for lung cancer.
The TD-SPFC faced certain limitations in developing a 
stage classification scheme. Despite the unprecedented size of 
the retrospective database that was assembled, the size of sub-
groups rapidly becomes smaller as one tries to examine more 
nuances. The relative paucity of data on patients not resected 
compounds this issue in patients with more advanced tumors—
such as those in which the N and M components are prominent. 
Furthermore, the advanced disease patients for whom data is 
available represent a skewed cohort, hampering the utility and 
validity of analyzing differences in outcomes. Finally, as in any 
retrospective database, there is missing data and lack of clarity 
in how details were defined at the source institutions.
However, we must remember that the purpose of stage 
classification is to develop a useful nomenclature. Considering 
outcomes is only a tool to accomplish this; furthermore, the 
observations must be interpreted with clinical insight into the 
entire spectrum of factors that affect outcomes—the anatomi-
cal extent of disease being only one factor that in some situa-
tions may contribute relatively little. The TD-SPFC sought to 
consider all factors not only the analysis of outcomes.
The proposed stage classification is only a step in an 
ongoing process. ITMIG has initiated prospective data collec-
tion which is much more detailed. Furthermore, the TD-SPFC 
will begin development of a prognostic prediction model. 
These initiatives should foster further progress in the future. 
In the meantime, the TD-SPFC hopes that the proposed clas-
sification will be found to be useful in providing a consistent 
language that facilitates collaboration around the world.
CONCLUSION
The proposals for the N and M components of stage 
classification in thymic malignancies described in this article 
represent the output of an initiative conducted by IASLC and 
ITMIG to develop a uniform official classification system 
that facilitates communication and collaboration around the 
world. This work was conducted over the course of 4 years, 
and involved extensive analysis of a large worldwide data-
base, as well as consideration of clinical and practical factors. 
Together with proposals for T classification and stage group-
ing, this provides a solid basis for stage classification of thy-
mic malignancies.
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